Page last updated: 2024-11-10

compound 348u87

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

compound 348U87: structure given in first source; antiherpes cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3006985
MeSH IDM0190136

Synonyms (12)

Synonym
1-(2-chlorophenyl)-3-[(1-pyridin-2-ylethylideneamino)carbamothioylamino]thiourea
carbonothioic dihydrazide, 2-(((2-chlorophenyl)amino)thioxomethyl)-21-(1-(2-pyridinyl)ethylidene)-
90ov2wy8jf ,
bw 348u87
2-actylpyridine 5-((2-chloroanilino)thiocarbonyl)thiocarbonohydrazone
348 u87
compound 348u87
unii-90ov2wy8jf
carbonothioic dihydrazide, 2-(((2-chlorophenyl)amino)thioxomethyl)-2'-(1-(2-pyridinyl)ethylidene)-
2-(((2-chlorophenyl)amino)thioxomethyl)-2'-(1-(2-pyridinyl)ethylidene)carbonothioic dihydrazide
n-(2-chlorophenyl)-2-({(2e)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide
PD067974

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study."( Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Corey, L; Delehanty, J; Hill, E; Safrin, S; Schacker, T, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" None of the novel ribonucleotide reductase inactivators was hematologically toxic to rats following oral dosing at 60 mg/kg/day for 30 days."( Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Blumenkopf, TA; Ellis, MN; Lobe, DC; Spector, T; Szczech, GM, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]